Navigation Links
Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
Date:4/9/2008

duction technologies, the strengths of the PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. These characteristics, combined with its ability to support the growth of both human and animal viruses, make PER.C6(R) technology the biopharmaceutical production technology of choice for Crucell's current and potential pharmaceutical and biotechnology partners.

About Aeras

The Aeras Global TB Vaccine Foundation (http://www.aeras.org) is a non-profit organization working as a Product Development Partnership to develop new tuberculosis vaccines and ensure that they are distributed to all who need them around the world. Aeras is funded by the Bill & Melinda Gates Foundation, the Netherlands Ministry of Foreign Affairs, the Danish International Development Agency, the Research Council of Norway and the U.S. Centers for Disease Control and Prevention. Aeras, with over 110 employees, is based in Rockville, Maryland, where it operates a state-of-the-art manufacturing and laboratory facility.

About Crucell

Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss: CRX.SW) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6(R) production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Im
'/>"/>

SOURCE Aeras Global TB Vaccine Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
2. Artists for a New South Africa Will be Shaking The Blues at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb Mo, Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles
3. Grammy Winner Marc Cohn to Perform for African AIDS Organization at Carolina HopeFest
4. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
7. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
8. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
9. Tampax and Always Launch Protecting Futures Program Dedicated to Helping African Girls Stay in School
10. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
11. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its second quarter 2014 financial results on Monday, August ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Monday, August ...
(Date:7/25/2014)... 25, 2014  Corporate libraries are constantly being faced ... in technology and how to cope with flat or ... pharmaceutical and medical device industries are increasingly finding it ... services they provide. According to recent ... many forces of change that leading corporate libraries are ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Forces of Change Reshaping Corporate Libraries & Information Services 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
... N.C., March 4, 2011 The pressure for a ... greater with organizations across the pharmaceutical sector facing pipeline ... Facing an ever-changing launch landscape, product launch leaders ... new therapies through the labyrinth of regulatory and marketplace ...
... 2011 Cardica, Inc. (Nasdaq: CRDC ) ... stapling device developed by Cardica has received CE Mark ... marking process, Cardica has obtained a Full Quality Assurance ... this certification, after successful completion of development, Cardica can ...
Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
(Date:7/28/2014)... With California in a record draught ... that a fire blanket that is over ... development by SunSeeker Enterprises, Inc. The fire blanket—utilizing the ... the extreme heat of re-entry into the Earth's atmosphere—will ... , “Our firefighters routinely lay their very lives on ...
(Date:7/28/2014)... July 28, 2014 At some point in ... where they’re forced to contact the authorities. Distinguishing the ... than it initially seems. , Not every dangerous situation is ... stolen, a person get mugged, or a bank get held ... leading onlookers to be more passive than they otherwise should. ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... July 28, 2014 The report ... Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, Animal ... to 2018” defines and segments the global industrial ... global value for industrial enzymes. It also identifies ... enzymes market with analysis of trends, opportunities, burning ...
(Date:7/28/2014)... School of Medicine (BUSM) report variants in a new ... Alzheimer,s disease (AD). The discovery of this novel genetic ... target PLXNA4 specifically. These findings appear in the ... frequent age-related dementia affecting 5.4 million Americans including 13 ... than 40 percent of people age 85 and older. ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2
... A recent study estimates that nearly 30,000 men will ... study offers hope for these patients: // The combination ... improves survival rates. ,AST inhibits the release of ... three years of AST with radiation therapy has been ...
... compression stockings can reduce complications after a blood clot ... uncomfortable .// ,Some of the common complications with ... leg include swelling, skin discoloration, numbness, chronic pain, hardening ... suggested that elastic stockings could help patients with blood ...
... of people worldwide . It is the most common form ... are still unknown and there is no cure. ,New ... to treating Alzheimer’s disease. A team of researchers tested ... were given sage oil capsules, and some were given placebos. ...
... to researchers a group of cells, called satellite cells, ... older people maintain // their youthfulness. These cells rescue ... They also generate new cells for future repairs. Previous ... protein called Notch is activated by another protein called ...
... Chronic obstructive pulmonary disease, an often neglected disease of the ... The vast majority of people with the disease are smokers. ... from wood fires also comes into play in some cases. ... in fact, it will be the third leading cause of ...
... news for the many adults and children who have endured ... ,Developing a vaccine to prevent group A streptococcal infections has ... years. Group A streptococcus is responsible for a variety of ... most common. ,The vaccine trial included 28 adults ...
Cached Medicine News:
The Advance Unicompartmental Knee System is designed with bone conserving femoral and tibial components that provide reproducible results within a minimal incision. Uni metal backed tibial component....
...
...
... Severe revision options for the knee and ... modular system for the knee and hip ... that include surgical indication, implant selection, connection ... individual needs. This system addresses the needs ...
Medicine Products: